☰

Erik W. Wilker, Ph.D.

Affiliations: 
2001 University of Texas at Austin, Austin, Texas, U.S.A. 
Area:
Pharmacology and Toxicology
Google:
"Erik Wilker"
Mean distance: 15925.2
 
Tree Publications Similar researchers PubMed Report error

Parents

Sign in to add mentor
John DiGiovanni grad student 2001 UT Austin
 (Role of insulin -like growth factor I in mouse skin tumor promotion.)

Children

Sign in to add trainee

Collaborators

Sign in to add collaborator
BETA: Related publications

Publications

You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Simoneau A, Engel JL, Bandi M, et al. (2022) Ubiquitinated PCNA drives USP1 synthetic lethality in cancer. Molecular Cancer Therapeutics
Shields JA, Meier SR, Bandi M, et al. (2022) VRK1 is a Synthetic Lethal Target in VRK2-deficient Glioblastoma. Cancer Research
DeSelm L, Huck B, Lan R, et al. (2021) Identification of Clinical Candidate M2698, a Dual p70S6K and Akt Inhibitor, for Treatment of PAM Pathway-Altered Cancers. Journal of Medicinal Chemistry
Xiao Y, Huck BR, Lan R, et al. (2021) Discovery of 4-Aminopyrimidine Analogs as highly Potent Dual P70S6K/Akt Inhibitors. Bioorganic & Medicinal Chemistry Letters. 128352
Machl A, Wilker EW, Tian H, et al. (2016) M2698 is a potent dual-inhibitor of p70S6K and Akt that affects tumor growth in mouse models of cancer and crosses the blood-brain barrier. American Journal of Cancer Research. 6: 806-18
Banko MR, Allen JJ, Schaffer BE, et al. (2011) Chemical genetic screen for AMPKα2 substrates uncovers a network of proteins involved in mitosis. Molecular Cell. 44: 878-92
Yi C, Wilker EW, Yaffe MB, et al. (2008) Validation of the p21-activated kinases as targets for inhibition in neurofibromatosis type 2 Cancer Research. 68: 7932-7937
Lu J, Rho O, Wilker E, et al. (2007) Activation of epidermal akt by diverse mouse skin tumor promoters. Molecular Cancer Research : McR. 5: 1342-52
Charest A, Wilker EW, McLaughlin ME, et al. (2006) ROS fusion tyrosine kinase activates a SH2 domain-containing phosphatase-2/phosphatidylinositol 3-kinase/mammalian target of rapamycin signaling axis to form glioblastoma in mice. Cancer Research. 66: 7473-81
Wilker E, Lu J, Rho O, et al. (2005) Role of PI3K/Akt signaling in insulin-like growth factor-1 (IGF-1) skin tumor promotion. Molecular Carcinogenesis. 44: 137-45
See more...